PF-3845 is a potent, highly selective, covalent FAAH inhibitor with Ki of 0.23 uM, highly selective for FAAH in the brain.
PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.
PF-3845 displays an unprecedented combination of in vivo activity and selectivity.
PF-3845 selectively inhibits FAAH in vivo as determined by activity-based protein profiling and raises brain anandamide levels for up to 24 hrs, resulting in profound cannabinoid receptor-dependent reductions in inflammatory pain.
PF-3845 is a valuable pharmacological tool for studying FAAH-regulated endocannabinoid pathways.
